Dexamethasone Reduces Mortality In Seriously Ill Covid-19 Patients—And So Do Other Treatments

Each day doctors are battling to save lives with the limited resources they have. They hope, as do we, that medical science will soon lend them a strong helping hand.

A group of doctors announced today they had completed a controlled study in which they compared the survival of patients seriously ill with Covid-19 with those on standard care. The seriously ill included those who need oxygen support and those in intensive care units with breathing assistance.

More than 2,000 patients were treated with dexamethasone, a low-dose steroid. Their health outcomes were compared with more than 4,000 others who received standard care.

The results are encouraging. Dexamethasone treatment reduced the death rate of those needing breathing assistance by 35% and those needing oxygen support by 20%. This report adds to other smaller studies supporting the use of steroids in Covid-19 patients requiring oxygen support.

However, the Oxford team erroneously claimed that this was the first medication to improve the survival of seriously ill Covid-19 patients—a claim repeated in headlines around the world.

Read full article on Forbes

Originally published on Forbes (June 16, 2020)

© William A. Haseltine, PhD. All Rights Reserved.